| Transport Package: | Free |
|---|---|
| Specification: | 75iu |
| Trademark: | Sinolead |
| Origin: | China |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Generic Name | Urofollitropin for Injection 75iu |
| Strength | 75iu |
| Packing | 1 vial+1 ampoule/box |
| Origin | China |
This product is white or white freeze-dried lump or powder.
1. For those who do not ovulate (including polycystic ovary syndrome) and do not respond to clomiphene citrate treatment.
2. For assisted reproductive technology for hyperovulation.
Usage and dosage:
This product can be used for intramuscular injection. The powder can be dissolved in sodium chloride injection before injection. In order to avoid excessive injection volume, 5 bottles of this product can be dissolved in 1ml solvent.
1. For those who do not ovulate (including polycystic ovary syndrome) and do not respond to clomiphene citrate treatment.
The therapeutic purpose of this product is to produce a single mature Graff follicle and then use HCG to induce egg release.
This product can be injected daily over a course of treatment, and in patients with menstruation, treatment should begin within the first seven days of the menstrual cycle.
The treatment regimen should be adjusted according to the patient's response. The usual treatment regimen begins with injections of FSH up to 75-150 units per day, with 75 units per day increased or decreased at intervals of 7 or 14 days if necessary to obtain a moderate (not excessive) response, and if the response to treatment is still poor after 4 weeks, treatment should be stopped for this cycle.
If the response is moderate, a single intramuscular dose of 10,000 units of HCG should be given 24-48 hours after the last injection of this product, and the patient is advised to have sex on the day or day after the application of HCG.
If the reaction is excessive, treatment should be stopped and HCG should no longer be used, and a lower dose regimen should be applied in the next cycle than in the previous cycle.
2, for assisted reproductive technology to promote ovulation.
Treatment options for hyperovulating women include starting on day 2 or 3 of the menstrual cycle with 150-225 units of this product per day, adjusting the dose according to the patient's response (the maximum daily dose does not exceed 450 units), and continuing treatment until adequate follicular development is achieved.
A single dose of 10,000 units of HCG is administered 24-48 hours after the last injection of this product to induce final maturation of follicles.
Down-regulation of GnRH agonists is now widely used to suppress endogenous LH peaks and control LH levels, and in the usual medication regimen, it is generally started nearly two weeks after agonist treatment, and both drugs are continued until adequate follicular development is achieved.
For example, 225 units of this product may be injected intramuscular during the first seven days, with subsequent doses adjusted according to the therapeutic response of the ovaries.
Matters needing attention:
1. Reconfirm the diagnosis of marital infertility before the start of treatment and infer whether it is an indication.
2. Adhere to the recommended therapeutic dose and monitor the treatment regimen to reduce the occurrence of ovarian hyperstimulation, which has been clinically proven to occur in less than 1% of patients.
3. The use of this product to treat excessive ovarian response generally does not induce significant adverse reactions, unless HCG is used to induce ovulation or
A pregnancy has occurred. Ovarian hyperstimulation syndrome usually occurs 1-2 weeks after HCG treatment or ovulation.
4. If symptoms such as pelvic pain, abdominal distension, or ovarian enlargement occur, or estrogen measurement or ultrasound examination indicates excessive estrogen response, the treatment of this product should be discontinued and HCG therapy should not be taken, and sexual intercourse should be avoided to prevent ovarian overstimulation.
5. There may be ascites, pericardial effusion, pleural hydrops, blood concentration, secondary aldosteronism, or hypercoagulability. These symptoms should be controlled by appropriate medical measures, including avoiding unnecessary pelvic examinations, and if pregnancy does not occur, these symptoms usually go away on their own after the onset of menstruation.
6. For patients with a history of lactose allergy, it must be taken into account that this product contains lactose.
7. Waste drug packaging should not be discarded at will.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}